Developing The Next Generation Bispecific Antibody Drugs
We are dedicated to discover novel, first-in-class bispecific therapeutic antibodies to combat life threatening diseases such as cancer.
⦁ We use proprietary designed primers for phage library construction with PBMC samples from immunized Alpaca.
⦁ We own self-designed, optimized novel synthetic single-domain (VHH) antibody library, with diversity > 1010.
⦁ We use cutting-edge technology and state-of-the-art screening platform for VHH antibody discovery, using MOA mimic in vitro and ex vivo assays to evaluate and select functional antibodies.